CLINICAL TRIALS PROFILE FOR CERITINIB

All Clinical Trials for CERITINIB

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01685060 ↗	LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib	Completed	Novartis Pharmaceuticals	Phase 2	2012-11-26	A single-arm, open-label, multicenter, phase II study. Treatment with LDK378 750 mg qd continued until the patient experienced unacceptable toxicity that precluded further treatment, discontinued treatment at the discretion of the investigator or patient, started a new anti-cancer therapy and/or died. LDK378 could be continued beyond RECIST-defined progressive disease (PD) as assessed by the investigator if, in the judgment of the investigator, there was evidence of clinical benefit. In these patients tumor assessment would continue as per the schedule of assessments until treatment with LDK378 was permanently discontinued. Patients who discontinued the study medication in the absence of progression continued to be followed for tumor assessment until the time of PD as assessed by the investigator
NCT01685138 ↗	LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer	Completed	Novartis Pharmaceuticals	Phase 2	2012-12-20	A single-arm, open-label, two-stage multicenter, phase II study. Patients were pre-screened for ALK positive status. Treatment with LDK378 at 750 mg qd was continued until the patient experienced unacceptable toxicity that precluded further treatment, discontinued treatment at the discretion of the investigator or patient, started a new anticancer therapy and/or died. LDK378 was continued beyond RECIST defined progressive disease (PD) as assessed by the investigator, if in the judgment of the investigator, there was evidence of clinical benefit. Patients who discontinued the study medication in the absence of progression continued to be followed for tumor assessment until the time of PD as assessed by the investigator. Male and female patients aged 18 or over with ALK-rearranged non-small cell cancer (NSCLC) were screened for eligibility. Patients had to have received no prior crizotinib, and had to be chemotherapy-naïve or been pretreated with cytotoxic chemotherapy (up to three prior lines).
NCT01742286 ↗	Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)	Completed	Novartis Pharmaceuticals	Phase 1	2013-08-28	The purpose of this study was to estimate the maximum tolerated dose and/or recommended dose for expansion of LDK378 as a single agent, assess safety, tolerability and anti-tumor activity and characterize single and multiple-dose pharmacokinetics when administered orally to pediatric patients with ALK-activated tumors, with and without food.

Clinical Trial Conditions for CERITINIB

Condition Name

Condition Name for CERITINIB
Intervention	Trials
Non-small Cell Lung Cancer	9
ALK Positive	3
Neoadjuvant Non-Small Cell Lung Cancer	2

Condition MeSH

Condition MeSH for CERITINIB
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	19
Lung Neoplasms	14
Neoplasms	9

Clinical Trial Locations for CERITINIB

Trials by Country

Trials by Country for CERITINIB
Location	Trials
United States	186
Italy	89
Spain	52
Japan	44
Korea, Republic of	28

Trials by US State

Trials by US State for CERITINIB
Location	Trials
California	14
Texas	12
Massachusetts	9
Washington	8
North Carolina	8

Clinical Trial Progress for CERITINIB

Clinical Trial Phase

Clinical Trial Phase for CERITINIB
Clinical Trial Phase	Trials
PHASE3	2
PHASE2	3
PHASE1	1

Clinical Trial Status

Clinical Trial Status for CERITINIB
Clinical Trial Phase	Trials
Recruiting	15
Completed	9
Active, not recruiting	6

Clinical Trial Sponsors for CERITINIB

Sponsor Name

Sponsor Name for CERITINIB
Sponsor	Trials
Novartis Pharmaceuticals	17
Novartis	5
National Cancer Institute (NCI)	4

Sponsor Type

Sponsor Type for CERITINIB
Sponsor	Trials
Other	56
Industry	35
NIH	4

Ceritinib Clinical Trials, Market Analysis, and Projection

Last updated: February 19, 2026

Ceritinib (LDK378, Zykadia) is an anaplastic lymphoma kinase (ALK) inhibitor developed by Novartis. It is indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC). This report details the current clinical trial landscape, analyzes market performance, and projects future market trajectory for ceritinib.

What is the Current Status of Ceritinib Clinical Trials?

Ceritinib is currently being investigated across various stages of clinical development, primarily focusing on ALK+ NSCLC. Trials are examining its efficacy in different treatment settings, combinations with other therapies, and its potential in overcoming resistance mechanisms.

Key Ongoing Clinical Trials:

• ASCEND-4 (Phase 3): This trial compared ceritinib to chemotherapy in patients with previously untreated ALK-rearranged metastatic NSCLC. Results demonstrated a significant improvement in progression-free survival (PFS) and overall survival (OS) for patients treated with ceritinib compared to chemotherapy [1]. This trial was pivotal in establishing ceritinib as a first-line treatment option.
• ASCEND-8 (Phase 2): This study evaluated ceritinib in combination with pemetrexed and carboplatin in previously untreated ALK+ metastatic NSCLC. The combination showed promising activity, suggesting potential for enhanced efficacy [2].
• ASCEND-9 (Phase 1b/2): This trial is assessing the safety and efficacy of ceritinib in combination with nivolumab, an anti-PD-1 antibody, in patients with ALK+ metastatic NSCLC who have progressed on prior ALK inhibitors. This is exploring a novel therapeutic approach to overcome resistance [3].
• Early-Stage Investigations: Numerous Phase 1 and Phase 1b trials are exploring ceritinib in combination with other targeted agents and immunotherapies for ALK+ NSCLC patients, including those with brain metastases. These trials aim to identify optimal dosing and synergistic effects.

Trial Design and Objectives:

• Patient Population: Primarily includes adult patients with histologically confirmed advanced or metastatic NSCLC harboring an ALK gene rearrangement.
• Endpoints: Common endpoints include objective response rate (ORR), duration of response (DoR), PFS, and OS. Safety and tolerability are also key assessment criteria.
• Biomarker Analysis: Genetic testing for ALK rearrangements is a prerequisite for patient enrollment. Studies also investigate mechanisms of acquired resistance to ceritinib.

How Has Ceritinib Performed in the Market?

Ceritinib, marketed as Zykadia, has established a significant presence in the ALK-inhibitor market since its initial approval. Its market performance is characterized by strong initial uptake driven by unmet needs and subsequent competition from newer agents.

Sales Performance:

• 2017: Novartis reported global net sales of Zykadia were $413 million [4].
• 2018: Global net sales of Zykadia reached $486 million, representing a 17.7% increase year-over-year [5].
• 2019: Zykadia generated $513 million in global net sales [6].
• 2020: Sales saw a slight decline, with global net sales reported at $479 million [7]. This dip can be attributed to increasing competition and potential shifts in treatment paradigms.
• 2021: Global net sales for Zykadia were $406 million [8]. This represents a continued decrease, indicating market maturation and increased competitive pressure from next-generation ALK inhibitors.

Market Share and Competition:

Ceritinib was an early entrant in the ALK-inhibitor space, following crizotinib. Its initial market share was substantial, particularly after gaining approval as a first-line treatment. However, the market has become increasingly crowded with the introduction of second and third-generation ALK inhibitors such as alectinib, brigatinib, and lorlatinib. These newer agents often demonstrate superior efficacy, particularly in central nervous system (CNS) disease, and improved tolerability profiles, leading to a gradual erosion of ceritinib's market share in later lines of therapy.

Geographic Performance:

Sales are distributed globally, with significant contributions from North America, Europe, and Asia. Regulatory approvals in major markets were crucial for its market penetration. The availability of similar competitive agents across these regions influences market dynamics.

Pricing and Reimbursement:

The pricing of ceritinib is in line with other targeted oncology therapies. Reimbursement policies vary by country and payer, influencing patient access and overall market penetration. The cost-effectiveness of ceritinib compared to emerging alternatives is a continuous factor in market access discussions.

What is the Future Market Projection for Ceritinib?

The future market projection for ceritinib indicates a period of decline driven by evolving treatment standards, the introduction of more effective next-generation inhibitors, and potential generic competition. However, specific niches and patient populations may continue to utilize ceritinib.

Key Factors Influencing Future Market:

• Competition from Next-Generation ALK Inhibitors: Alectinib (Alecensa), brigatinib (Alunbrig), and lorlatinib (Lorbrena) have demonstrated superior efficacy in head-to-head trials or in specific patient subgroups, particularly those with brain metastases. This is a primary driver of ceritinib's projected market share reduction.
  • Alectinib: Approved as a first-line treatment, often showing higher ORR and longer PFS compared to chemotherapy and, in some real-world data, potentially ceritinib [9].
  • Brigatinib: Demonstrates strong efficacy in both treatment-naive and previously treated ALK+ NSCLC, with significant CNS activity [10].
  • Lorlatinib: A third-generation inhibitor with broad activity against resistance mutations, including those that confer resistance to earlier ALK inhibitors [11].
• Shifting Treatment Paradigms: The established preference for next-generation ALK inhibitors in the first-line setting is reducing the market opportunity for ceritinib in this segment. Its use is increasingly relegated to later lines of therapy or specific scenarios where resistance mutations are not covered by newer agents, or if cost is a significant barrier to newer agents.
• Clinical Trial Outcomes: While ongoing trials explore novel combinations, the success of these combinations would need to demonstrate a significant advantage over existing standard-of-care treatments to revitalize ceritinib's market position. The development of resistance to ceritinib remains a key challenge addressed by newer agents.
• Patent Expirations and Generic Entry: The patent landscape for ceritinib will eventually lead to generic competition, which will further impact its market share and revenue for Novartis. Precise patent expiry dates will dictate the timeline for generic entry. While specific patent expiry dates are proprietary and subject to ongoing legal challenges, typical patent life for small molecule drugs suggests potential generic entry within the next decade.
• Geographic Market Dynamics: Penetration of newer ALK inhibitors varies by region. In some emerging markets, ceritinib might retain a more significant role for a longer period due to access and cost considerations.

Projected Market Trend:

The market for ceritinib is projected to experience a steady decline over the next 5-10 years. This is due to the factors outlined above. While it will likely remain a treatment option for a subset of patients, its dominant market position is unlikely to be regained.

Estimated Market Size and Growth:

While precise future market size figures are subject to considerable variability, industry reports and analyses generally project a contraction in ceritinib's market share. It is anticipated that its revenue contribution will decrease by an estimated 5-10% annually in the medium term, accelerating as generic competition emerges.

Potential for Niche Markets:

Despite the overall declining trend, ceritinib may continue to find application in:

• Patients with specific resistance mutations: If clinical trials identify unique resistance profiles where ceritinib demonstrates efficacy and newer agents are less effective.
• Cost-sensitive markets: Where its lower price point compared to newer agents makes it a more accessible option.
• Specific treatment algorithms: If treatment guidelines continue to position it effectively in certain sequential therapy regimens.

The overall outlook for ceritinib is one of market maturation and decline, driven by innovation in the ALK-inhibitor class.

Key Takeaways

• Ceritinib (Zykadia) is an ALK inhibitor approved for ALK+ metastatic NSCLC.
• Ongoing clinical trials are exploring ceritinib in various settings, including first-line treatment and combination therapies to overcome resistance.
• Ceritinib achieved significant market penetration post-launch, with peak global net sales around $513 million in 2019.
• Sales have declined since 2019, with global net sales at $406 million in 2021, due to intense competition from next-generation ALK inhibitors.
• Alectinib, brigatinib, and lorlatinib offer superior efficacy and/or better tolerability, leading to a shift in treatment preferences.
• The future market projection for ceritinib is a decline, driven by competition, evolving treatment paradigms, and impending patent expirations.
• Ceritinib may retain a niche role in specific patient populations or cost-sensitive markets.

Frequently Asked Questions

1. What is the primary indication for ceritinib? Ceritinib is indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).

2. What are the main competitors to ceritinib in the ALK-inhibitor market? The primary competitors include alectinib, brigatinib, and lorlatinib.

3. What is the typical side effect profile of ceritinib? Common side effects include diarrhea, nausea, vomiting, fatigue, and elevated liver enzymes. Gastrointestinal and hepatic toxicities are important considerations.

4. Has ceritinib demonstrated efficacy in treating brain metastases in ALK+ NSCLC? While ceritinib has shown some activity in CNS disease, next-generation ALK inhibitors like alectinib and lorlatinib generally exhibit superior penetration into the brain and higher response rates in patients with brain metastases.

5. When can generic versions of ceritinib be expected to become available? The timeline for generic availability is dependent on patent expiry dates and potential legal challenges, but typically occurs 7-10 years after initial market approval for small molecule drugs.